Santiago, Chile – On May 17, 2024, MicroPort^® CardioFlow Medtech Corporation(" MicroPort^® CardioFlow ", 02160.HK ) completed the first implantation with its self-developed VitaFlow Liberty^® Transcatheter Aortic Valve and Retrievable Delivery System (VitaFlow Liberty^® ) at the Sótero del Río Hospital in Chile. Dr. Martín Valdebenito, the director of cardiology at the hospital, and Dr. Juan Pablo De Brahi, a renowned Argentine cardiologist, performed the procedure and successfully treated a patient with severe aortic valve stenosis, with no conduction blocks or paravalvular leaks occurring and the transvalvular pressure gradient dropped to 4mmHg postoperatively. The patient was discharged within three days after the successful implantation.

Patient Baseline Information
The patient was a 79-year-old male with severe aortic valve stenosis，meeting the indications for TAVI based on the echocardiography and CT findings. The medical education and clinical team from CardioFlow, and Argentine expert team conducted thorough preoperative communication, jointly analyzing the patient's anatomical structure and developing a valve implantation strategy.

The patient had a tricuspid aortic valve with mild calcification based on CT assessment, with the annulus circumference of 84.1mm as well as the average diameter of 26.8mm, and the LVOT (left ventricular outflow tract) circumference of 81.1mm as well as the average diameter of 25.5mm.

Surgical Strategy and Procedure

1. A gentle right femoral artery access is chosen due to the tortuous approach of both the left and right femoral arteries in the patient.
2. Gentle treatment is equired during passage due to the presence of calcification in the patient's aortic arch.
3. Pre dilating with a small sized balloon in advance is recommended due to the presence of extended calcification from the aortic annulus to LVOT, and the VitaFlow Liberty^® with the TAV 30 valve was preferred to provide better hemodynamics postoperatively for the patient.

The patient benefited significantly from the implantation. Immediate postoperative angiography showed good valve morphology and position. Echocardiography revealed no paravalvular leaks, and the average transvalvular pressure gradient dropped to 4mmHg, with no conduction blocks occurring. The patient was discharged within three days after the successful implantation.

The "electric retrievable" design advantage of the delivery system allowed VitaFlow Liberty^® to demonstrate convenience, precision, and stability in clinical applications, leaving a profound impression on the experts present.

After the procedure, Dr. Martín Valdebenito remarked:
"VitaFlow Liberty^® provided tremendous convenience for physicians. Although perfoming the procedure with this valve for the first time, I found the learning curve very fast. The valve release process was simple and smooth during the operation, and the precision of the delivery system release as well as the stability of the valve impressed me. I look forward to further collaboration in the future to benefit more Chilean patients."

Currently, The VitaFlow^® series TAVI solution along with its accessory - the Alwide^® series Balloon Catheter, has successfully entered nearly 700 core hospitals in 10 countries and regions. In April this year, MicroPort^® CardioFlow 's VitaFlow Liberty^® received the EU CE-MDR certification, becoming the first domestically developed TAVI system approved by EU , marking the acceleration of its global strategic layout. In the future, MicroPort^® CardioFlow will continue to actively promote global market expansion and innovative research and development, strives to provide total solutions for structural heart diseases, dedicated to providing high quality therapeutic solutions to patients and physicians in Chile and worldwide.